{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:50:07Z","timestamp":1791856207175,"version":"4.3.4"},"reference-count":98,"publisher":"National Institute for Health and Care Research","issue":"2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["15\/110\/02"],"award-info":[{"award-number":["15\/110\/02"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Bacterial vaginosis is a common and distressing condition associated with serious comorbidities. Antibiotic treatment is usually clinically effective in the short term, but recurrence is common and side effects can occur.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n The objective is to assess whether or not intravaginal lactic acid gel is clinically effective and cost-effective for treating recurrent bacterial vaginosis compared with oral metronidazole (Flagyl, Sanofi).<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n This was an open-label, multicentre, parallel-arm, randomised (1\u2009:\u20091) controlled trial.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n This took place in one general practice and 19 sexual health centres in the UK.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Women aged \u2265\u200916 years with bacterial vaginosis symptoms and one or more episode(s) within the past 2 years took part.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n The interventions were 5\u2009ml of intravaginal lactic acid gel taken once daily for 7 days (intervention) or 400-mg oral metronidazole tablets taken twice daily for 7 days (control).<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n The primary outcome was the resolution of bacterial vaginosis symptoms 14 days after randomisation. The secondary outcomes were time to first recurrence of symptoms; number of recurrences and treatment courses over 6 months; microbiological resolution on microscopy of vaginal smears at week 2; time to resolution of symptoms; tolerability, adherence and acceptability of the treatment; prevalence of concurrent sexually transmitted infections; quality of life; and cost-effectiveness.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Recruitment stopped prior to reaching the target of 1900 participants on recommendation from the Data Monitoring Committee and Trial Steering Committee after a planned review of the results indicated that the research question had been answered. Overall, 518 participants were randomised and primary outcome data were available for 409 participants (79%; 204 in the metronidazole arm, 205 in the lactic acid gel arm). Participant-reported symptom resolution at week 2 was higher with metronidazole (143\/204; 70%) than with lactic acid gel (97\/205; 47%) (adjusted risk difference \u201323.2%, 95% confidence interval \u201332.3% to \u201314.0%). Recurrence in 6 months in a subset of participants who had initial resolution and were available for follow-up was similar across arms (metronidazole arm: 51\/72, 71%; lactic acid gel arm: 32\/46, 70%). A higher incidence of some side effects was reported with metronidazole than with lactic acid gel (nausea 32% vs. 8%; taste changes 18% vs. 1%; diarrhoea 20% vs. 6%, respectively). At week 2, the average cost per participant with resolved symptoms was \u00a386.94 (metronidazole), compared with \u00a3147.00 (lactic acid gel). Some participants preferred using lactic acid gel even if they perceived it to be less effective than metronidazole.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Loss to follow-up for collection of the primary outcome data was 21% and was similar in both arms. There is a risk of bias owing to missing outcome data at 3 and 6 months post treatment.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n A higher initial response was seen with metronidazole than with lactic acid gel, but subsequent treatment failure was common with both. Lactic acid gel was less cost-effective than metronidazole. In general, women disliked taking repeated courses of metronidazole and preferred lactic acid gel, even when they were aware that it was less likely to provide symptom resolution. In the absence of effective curative therapy, further evaluation of non-antibiotic treatments to control the symptoms of recurrent bacterial vaginosis is required to improve quality of life for these patients. Further microbiological analysis of vaginal samples would be useful to identify additional factors affecting response to treatment.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n Current Controlled Trials ISRCTN14161293.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 26, No. 2. See the NIHR Journals Library website for further project information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/zzkh4176","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T09:10:21Z","timestamp":1642669821000},"page":"1-170","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT"],"prefix":"10.3310","volume":"26","clinical-trial-number":[{"clinical-trial-number":"isrctn14161293","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8045-5464","authenticated-orcid":true,"given":"Lindsay","family":"Armstrong-Buisseret","sequence":"first","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-0733","authenticated-orcid":true,"given":"Clare","family":"Brittain","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-9384","authenticated-orcid":true,"given":"Joe","family":"Kai","sequence":"additional","affiliation":[{"name":"Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6756-0550","authenticated-orcid":true,"given":"Miruna","family":"David","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-1057","authenticated-orcid":true,"given":"Jocelyn","family":"Anstey Watkins","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-9807","authenticated-orcid":true,"given":"Mara","family":"Ozolins","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8492-0020","authenticated-orcid":true,"given":"Louise","family":"Jackson","sequence":"additional","affiliation":[{"name":"Health Economics Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2736-5427","authenticated-orcid":true,"given":"Zainab","family":"Abdali","sequence":"additional","affiliation":[{"name":"Health Economics Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-6696","authenticated-orcid":true,"given":"Trish","family":"Hepburn","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4173-1438","authenticated-orcid":true,"given":"Frances","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"},{"name":"Centre for Health Policy, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0450-1606","authenticated-orcid":true,"given":"Alan","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3324-6771","authenticated-orcid":true,"given":"Jane","family":"Daniels","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3804-1751","authenticated-orcid":true,"given":"Alice","family":"Manley","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medicine, Whittall Street Clinic, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5599-2594","authenticated-orcid":true,"given":"Gillian","family":"Dean","sequence":"additional","affiliation":[{"name":"Elton John Research Centre, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4193-6919","authenticated-orcid":true,"given":"Jonathan DC","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medicine, Whittall Street Clinic, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2022,1]]},"reference":[{"key":"key20220120132439431_ref1-bib1","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1097\/QAD.0b013e3283021a37","article-title":"Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies","volume":"22","author":"Atashili","year":"2008","journal-title":"AIDS"},{"key":"key20220120132439431_ref1-bib2","doi-asserted-by":"publisher","first-page":"e1001251","DOI":"10.1371\/journal.pmed.1001251","article-title":"Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples","volume":"9","author":"Cohen","year":"2012","journal-title":"PLOS Med"},{"key":"key20220120132439431_ref1-bib3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/aje\/kwi243","article-title":"A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease","volume":"162","author":"Ness","year":"2005","journal-title":"Am J Epidemiol"},{"key":"key20220120132439431_ref1-bib4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1067\/mob.2003.167","article-title":"Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis","volume":"188","author":"Leitich","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"key20220120132439431_ref1-bib5","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.12688\/f1000research.11417.1","article-title":"Bacterial vaginosis [version 1; peer review: 2 approved]","volume":"6","author":"Hay","year":"2017","journal-title":"F1000Res"},{"key":"key20220120132439431_ref1-bib6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.nurpra.2019.03.010","article-title":"Bacterial vaginosis: a review of treatment, recurrence, and disparities","volume":"15","author":"Jones","year":"2019","journal-title":"J Nurse Pract"},{"key":"key20220120132439431_ref1-bib7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/01.JAA.0000526770.60197.fa","article-title":"Bacterial vaginosis: a practical review","volume":"30","author":"Bagnall","year":"2017","journal-title":"JAAPA"},{"key":"key20220120132439431_ref1-bib8","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1086\/648093","article-title":"Bacterial vaginosis: are we coming full circle?","volume":"200","author":"Schwebke","year":"2009","journal-title":"J Infect Dis"},{"key":"key20220120132439431_ref1-bib9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/OLQ.0000000000000972","article-title":"High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis","volume":"46","author":"Peebles","year":"2019","journal-title":"Sex Transm Dis"},{"key":"key20220120132439431_ref1-bib10","unstructured":"British Association for Sexual Health and HIV (BASHH). UK National Guideline for the Management of Bacterial Vaginosis 2012. Lichfield: BASHH; 2012."},{"key":"key20220120132439431_ref1-bib11","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"Recomm Rep"},{"key":"key20220120132439431_ref1-bib12","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1086\/503780","article-title":"High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence","volume":"193","author":"Bradshaw","year":"2006","journal-title":"J Infect Dis"},{"key":"key20220120132439431_ref1-bib13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1365-2125.2005.02550.x","article-title":"A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis","volume":"61","author":"Simoes","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"key20220120132439431_ref1-bib14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/clinids\/20.supplement_1.s72","article-title":"Bacterial vaginosis: review of treatment options and potential clinical indications for therapy","volume":"20","author":"Joesoef","year":"1995","journal-title":"Clin Infect Dis"},{"key":"key20220120132439431_ref1-bib15","volume-title":"Sexually Transmitted Infections (STIs): Annual Data Tables: Table 4","author":"Public Health England","year":"2018"},{"key":"key20220120132439431_ref1-bib16","volume-title":"Tackling Antimicrobial Resistance 2019\u201324. The UK\u2019s Five-year National Action Plan","author":"HM Government","year":"2019"},{"key":"key20220120132439431_ref1-bib17","volume-title":"A European One Health Action Plan Against Antimicrobial Resistance (AMR)","author":"European Commission","year":"2017"},{"key":"key20220120132439431_ref1-bib18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejogrb.2004.10.011","article-title":"Successful treatment of bacterial vaginosis with a policarbophil-carbopol acidic vaginal gel: results from a randomised double-blind, placebo-controlled trial","volume":"120","author":"Fiorilli","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key20220120132439431_ref1-bib19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/sti.69.5.388","article-title":"Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial","volume":"69","author":"Boeke","year":"1993","journal-title":"Genitourin Med"},{"key":"key20220120132439431_ref1-bib20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/01.OLQ.0000118423.20985.E7","article-title":"A randomized, double-blind clinical trial of vaginal acidification versus placebo for the treatment of symptomatic bacterial vaginosis","volume":"31","author":"Holley","year":"2004","journal-title":"Sex Transm Dis"},{"key":"key20220120132439431_ref1-bib21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000298923","article-title":"Treatment of bacterial vaginosis with an acid cream: a comparison between the effect of lactate-gel and metronidazole","volume":"21","author":"Andersch","year":"1986","journal-title":"Gynecol Obstet Invest"},{"key":"key20220120132439431_ref1-bib22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000293556","article-title":"Bacterial vaginosis is not a simple ecological disorder","volume":"28","author":"Fredricsson","year":"1989","journal-title":"Gynecol Obstet Invest"},{"key":"key20220120132439431_ref1-bib23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1447-0756.2006.00383.x","article-title":"Metronidazole with Lactacyd vaginal gel in bacterial vaginosis","volume":"32","author":"Decena","year":"2006","journal-title":"J Obstet Gynaecol Res"},{"key":"key20220120132439431_ref1-bib24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jama.1992.03490010094036","article-title":"Comparison of different metronidazole therapeutic regimens for bacterial vaginosis. A meta-analysis","volume":"268","author":"Lugo-Miro","year":"1992","journal-title":"JAMA"},{"key":"key20220120132439431_ref1-bib25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1186\/s13063-019-3731-7","article-title":"Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis","volume":"20","author":"Armstrong-Buisseret","year":"2019","journal-title":"Trials"},{"key":"key20220120132439431_ref1-bib26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1745-6215-11-32","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"11","author":"Schulz","year":"2010","journal-title":"Trials"},{"key":"key20220120132439431_ref1-bib27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"key":"key20220120132439431_ref1-bib28","unstructured":"Great Britain. The Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994. London: The Stationery Office; 1994."},{"key":"key20220120132439431_ref1-bib29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/sti.78.6.413","article-title":"Validation of a simplified grading of Gram stained vaginal smears for use in genitourinary medicine clinics","volume":"78","author":"Ison","year":"2002","journal-title":"Sex Transm Infect"},{"key":"key20220120132439431_ref1-bib30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/jac\/41.1.6","article-title":"Therapy of bacterial vaginosis","volume":"41","author":"Hay","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"key20220120132439431_ref1-bib31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/095646249200300402","article-title":"Treatment of bacterial vaginosis","volume":"3","author":"Larsson","year":"1992","journal-title":"Int J STD AIDS"},{"key":"key20220120132439431_ref1-bib32","first-page":"963","article-title":"Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis","volume":"81","author":"Hillier","year":"1993","journal-title":"Obstet Gynecol"},{"key":"key20220120132439431_ref1-bib33","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1177\/0956462418785451","article-title":"2018 European (IUSTI\/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge","volume":"29","author":"Sherrard","year":"2018","journal-title":"Int J STD AIDS"},{"key":"key20220120132439431_ref1-bib34","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.3399\/bjgp16X686533","article-title":"Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance","volume":"66","author":"Oppong","year":"2016","journal-title":"Br J Gen Pract"},{"key":"key20220120132439431_ref1-bib35","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013. URL: www.ncbi.nlm.nih.gov\/books\/NBK395867\/ (accessed 27 April 2020)."},{"key":"key20220120132439431_ref1-bib36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) \u2013 explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"key20220120132439431_ref1-bib37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1477-7525-7-40","article-title":"Assessing the empirical validity of alternative multi-attribute utility measures in the maternity context","volume":"7","author":"Petrou","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"key20220120132439431_ref1-bib38","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","article-title":"The estimation of a preference-based measure of health from the SF-12","volume":"42","author":"Brazier","year":"2004","journal-title":"Med Care"},{"key":"key20220120132439431_ref1-bib39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"key":"key20220120132439431_ref1-bib40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials \u2013 a practical guide with flowcharts","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"key20220120132439431_ref1-bib41","volume-title":"Unit Costs of Health and Social Care 2019","author":"Curtis","year":"2019"},{"key":"key20220120132439431_ref1-bib42","volume-title":"National Cost Collection 2019","author":"NHS","year":"2020"},{"key":"key20220120132439431_ref1-bib43","volume-title":"British National Formulary","author":"Joint Formulary Committee"},{"key":"key20220120132439431_ref1-bib44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/qjmed\/92.3.177","article-title":"Bootstrapping: estimating confidence intervals for cost-effectiveness ratios","volume":"92","author":"Campbell","year":"1999","journal-title":"QJM"},{"key":"key20220120132439431_ref1-bib45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1586\/14737167.1.1.25","article-title":"Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses","volume":"1","author":"Glick","year":"2001","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"key":"key20220120132439431_ref1-bib46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/0272989X9001000308","article-title":"The CE plane: a graphic representation of cost-effectiveness","volume":"10","author":"Black","year":"1990","journal-title":"Med Decis Making"},{"key":"key20220120132439431_ref1-bib47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13756-018-0384-3","article-title":"Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use","volume":"7","author":"Shrestha","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"key20220120132439431_ref1-bib48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II \u2013 an ISPOR Good Research Practices Task Force report","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health"},{"key":"key20220120132439431_ref1-bib49","volume-title":"Applied Methods of Cost-effectiveness Analysis in Healthcare","author":"Gray","year":"2010"},{"key":"key20220120132439431_ref1-bib50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/infdis\/jiw159","article-title":"Current treatment of bacterial vaginosis \u2013 limitations and need for innovation","volume":"214","author":"Bradshaw","year":"2016","journal-title":"J Infect Dis"},{"issue":"31","key":"key20220120132439431_ref1-bib51","doi-asserted-by":"publisher","DOI":"10.3310\/hsdr03310","article-title":"Care and communication between health professionals and patients affected by severe or chronic illness in community care settings: a qualitative study of care at the end of life","volume":"3","author":"Pollock","year":"2015","journal-title":"Health Serv Deliv Res"},{"key":"key20220120132439431_ref1-bib52","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12879-015-1027-4","article-title":"Making inroads into improving treatment of bacterial vaginosis \u2013 striving for long-term cure","volume":"15","author":"Bradshaw","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key20220120132439431_ref1-bib53","first-page":"43","article-title":"Acute and recurrent bacterial vaginosis","volume":"26","author":"Hull","year":"2016","journal-title":"Clin Rev"},{"key":"key20220120132439431_ref1-bib54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PPA.S24752","article-title":"A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence","volume":"6","author":"Barbosa","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"key20220120132439431_ref1-bib55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework","volume":"17","author":"Sekhon","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"key20220120132439431_ref1-bib56","doi-asserted-by":"publisher","first-page":"e74378","DOI":"10.1371\/journal.pone.0074378","article-title":"The burden of bacterial vaginosis: women\u2019s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis","volume":"8","author":"Bilardi","year":"2013","journal-title":"PLOS ONE"},{"key":"key20220120132439431_ref1-bib57","doi-asserted-by":"publisher","first-page":"e0224964","DOI":"10.1371\/journal.pone.0224964","article-title":"Acceptability of and treatment preferences for recurrent bacterial vaginosis \u2013 topical lactic acid gel or oral metronidazole antibiotic: qualitative findings from the VITA trial","volume":"14","author":"Anstey Watkins","year":"2019","journal-title":"PLOS ONE"},{"key":"key20220120132439431_ref1-bib58","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"key20220120132439431_ref1-bib59","doi-asserted-by":"publisher","first-page":"e0173637","DOI":"10.1371\/journal.pone.0173637","article-title":"Women view key sexual behaviours as the trigger for the onset and recurrence of bacterial vaginosis","volume":"12","author":"Bilardi","year":"2017","journal-title":"PLOS ONE"},{"key":"key20220120132439431_ref1-bib60","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/j.1365-2672.2011.04977.x","article-title":"The aetiology of bacterial vaginosis","volume":"110","author":"Turovskiy","year":"2011","journal-title":"J Appl Microbiol"},{"key":"key20220120132439431_ref1-bib61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1745-7599.2009.00474.x","article-title":"Evidence of African-American women\u2019s frustrations with chronic recurrent bacterial vaginosis","volume":"22","author":"Payne","year":"2010","journal-title":"J Am Acad Nurse Pract"},{"key":"key20220120132439431_ref1-bib62","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1097\/QAD.0b013e328346bd3e","article-title":"Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)","volume":"25","author":"McGowan","year":"2011","journal-title":"AIDS"},{"key":"key20220120132439431_ref1-bib63","first-page":"394","article-title":"Bacterial vaginosis \u2013 more questions than answers","volume":"38","author":"Pirotta","year":"2009","journal-title":"Aust Fam Physician"},{"key":"key20220120132439431_ref1-bib64","volume-title":"2015 Sexually Transmitted Diseases Treatment Guidelines. Bacterial Vaginosis","author":"Centers for Disease and Control Prevention","year":"2015"},{"key":"key20220120132439431_ref1-bib65","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00248-012-0154-3","article-title":"The restoration of the vaginal microbiota after treatment for bacterial vaginosis with metronidazole or probiotics","volume":"65","author":"Ling","year":"2013","journal-title":"Microb Ecol"},{"key":"key20220120132439431_ref1-bib66","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/OLQ.0000000000001178","article-title":"A narrative review of current challenges in the diagnosis and management of bacterial vaginosis","volume":"47","author":"Muzny","year":"2020","journal-title":"Sex Transm Dis"},{"key":"key20220120132439431_ref1-bib67","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/QCO.0b013e32832180c6","article-title":"Recurrent bacterial vaginosis","volume":"22","author":"Hay","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"key20220120132439431_ref1-bib68","doi-asserted-by":"publisher","first-page":"e00227","DOI":"10.1128\/JCM.00227-19","article-title":"Prognostic indicators of recurrence of bacterial vaginosis","volume":"57","author":"Sobel","year":"2019","journal-title":"J Clin Microbiol"},{"key":"key20220120132439431_ref1-bib69","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/QCO.0000000000000516","article-title":"The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment: 2018 update","volume":"32","author":"Verstraelen","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"key20220120132439431_ref1-bib70","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/olq.0000000000000414","article-title":"Recent biomarker-confirmed unprotected vaginal sex, but not self-reported unprotected sex, is associated with recurrent bacterial vaginosis","volume":"43","author":"Norris Turner","year":"2016","journal-title":"Sex Transm Dis"},{"key":"key20220120132439431_ref1-bib71","volume-title":"Metronodazole Summary of Product Characteristics","author":"Sanofi","year":"2019"},{"key":"key20220120132439431_ref1-bib72","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ajog.2005.11.041","article-title":"Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis","volume":"194","author":"Sobel","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"key20220120132439431_ref1-bib73","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ajog.2004.05.033","article-title":"Antimicrobial resistance associated with the treatment of bacterial vaginosis","volume":"191","author":"Beigi","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"key20220120132439431_ref1-bib74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diagmicrobio.2015.10.006","article-title":"Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis","volume":"84","author":"Schuyler","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key20220120132439431_ref1-bib75","doi-asserted-by":"publisher","first-page":"e00262","DOI":"10.1128\/mSphereDirect.00262-18","article-title":"Metatranscriptome analysis of the vaginal microbiota reveals potential mechanisms for protection against metronidazole in bacterial vaginosis","volume":"3","author":"Deng","year":"2018","journal-title":"mSphere"},{"key":"key20220120132439431_ref1-bib76","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1086\/506621","article-title":"The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy","volume":"194","author":"Bradshaw","year":"2006","journal-title":"J Infect Dis"},{"key":"key20220120132439431_ref1-bib77","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/infdis\/jiw622","article-title":"Impact of periodic presumptive treatment for bacterial vaginosis on the vaginal microbiome among women participating in the preventing vaginal infections trial","volume":"215","author":"Balkus","year":"2017","journal-title":"J Infect Dis"},{"key":"key20220120132439431_ref1-bib78","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-2036.1990.tb00467.x","article-title":"Review article: metronidazole and the anaerobic gut flora","volume":"4","author":"Elliott","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"key":"key20220120132439431_ref1-bib79","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1093\/infdis\/135.supplement.s95","article-title":"Clindamycin and colitis: a review","volume":"135","author":"Tedesco","year":"1977","journal-title":"J Infect Dis"},{"key":"key20220120132439431_ref1-bib80","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1345\/aph.17251","article-title":"Clostridium difficile toxin-induced colitis after use of clindamycin phosphate vaginal cream","volume":"32","author":"Meadowcroft","year":"1998","journal-title":"Ann Pharmacother"},{"key":"key20220120132439431_ref1-bib81","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.2147\/IDR.S213853","article-title":"Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses","volume":"12","author":"Sobel","year":"2019","journal-title":"Infect Drug Resist"},{"key":"key20220120132439431_ref1-bib82","doi-asserted-by":"publisher","first-page":"e34540","DOI":"10.1371\/journal.pone.0034540","article-title":"Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial","volume":"7","author":"Bradshaw","year":"2012","journal-title":"PLOS ONE"},{"key":"key20220120132439431_ref1-bib83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF02853158","article-title":"Potential patient preference for 3-day treatment of bacterial vaginosis: responses to new suppository form of clindamycin","volume":"17","author":"Broumas","year":"2000","journal-title":"Adv Ther"},{"key":"key20220120132439431_ref1-bib84","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/cid\/ciy554","article-title":"Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial","volume":"68","author":"Marrazzo","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key20220120132439431_ref1-bib85","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/1471-0528.15870","article-title":"Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs","volume":"127","author":"van de Wijgert","year":"2020","journal-title":"BJOG"},{"key":"key20220120132439431_ref1-bib86","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJMoa1915254","article-title":"Randomized trial of lactin-v to prevent recurrence of bacterial vaginosis","volume":"382","author":"Cohen","year":"2020","journal-title":"N Engl J Med"},{"key":"key20220120132439431_ref1-bib87","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11908-019-0688-3","article-title":"Lessons from suppressive therapy and periodic presumptive treatment for bacterial vaginosis","volume":"21","author":"Balkus","year":"2019","journal-title":"Curr Infect Dis Rep"},{"key":"key20220120132439431_ref1-bib88","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3389\/fphys.2015.00164","article-title":"Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis","volume":"6","author":"Aldunate","year":"2015","journal-title":"Front Physiol"},{"key":"key20220120132439431_ref1-bib89","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1067\/mob.2003.87","article-title":"Endometritis does not predict reproductive morbidity after pelvic inflammatory disease","volume":"188","author":"Haggerty","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"key20220120132439431_ref1-bib90","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/OLQ.0000000000001063","article-title":"Clinicians\u2019 use of intravaginal boric acid maintenance therapy for recurrent vulvovaginal candidiasis and bacterial vaginosis","volume":"46","author":"Powell","year":"2019","journal-title":"Sex Transm Dis"},{"key":"key20220120132439431_ref1-bib91","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11908-019-0700-y","article-title":"Vulvovaginitis caused by Candida species following antibiotic exposure","volume":"21","author":"Shukla","year":"2019","journal-title":"Curr Infect Dis Rep"},{"key":"key20220120132439431_ref1-bib92","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/01.olq.0000135990.21755.51","article-title":"Personal digital assistants used to document compliance of bacterial vaginosis treatment","volume":"31","author":"Bartley","year":"2004","journal-title":"Sex Transm Dis"},{"key":"key20220120132439431_ref1-bib93","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/OLQ.0b013e318073bd82","article-title":"Natural history of asymptomatic bacterial vaginosis in a high-risk group of women","volume":"34","author":"Schwebke","year":"2007","journal-title":"Sex Transm Dis"},{"key":"key20220120132439431_ref1-bib94","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1258\/0956462971920631","article-title":"A longitudinal study of the vaginal flora over a menstrual cycle","volume":"8","author":"Keane","year":"1997","journal-title":"Int J STD AIDS"},{"key":"key20220120132439431_ref1-bib95","doi-asserted-by":"publisher","first-page":"365194","DOI":"10.1155\/2013\/365194","article-title":"Comparison of Hay\u2019s criteria with Nugent\u2019s scoring system for diagnosis of bacterial vaginosis","volume":"2013","author":"Chawla","year":"2013","journal-title":"Biomed Res Int"},{"key":"key20220120132439431_ref1-bib96","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1034\/j.1600-0463.2002.1101107.x","article-title":"An international study of the interobserver variation between interpretations of vaginal smear criteria of bacterial vaginosis","volume":"110","author":"Forsum","year":"2002","journal-title":"APMIS"},{"key":"key20220120132439431_ref1-bib97","volume-title":"Services and Commissioning","author":"Pharmaceutical Services Negotiating Committee","year":"2020"},{"key":"key20220120132439431_ref1-bib98","volume-title":"Reference Costs 2017\/18","author":"NHS","year":"2018"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/ZZKH4176\/ZZKH4176.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:39:15Z","timestamp":1692099555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/ZZKH4176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":98,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["10.3310\/ZZKH4176"],"URL":"https:\/\/doi.org\/10.3310\/zzkh4176","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"3-2017","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"10-2020","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"1-2021","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}